Inspire Medical Systems, Inc. (NYSE:INSP) Receives $271.29 Consensus Price Target from Brokerages

Shares of Inspire Medical Systems, Inc. (NYSE:INSP) have received a consensus rating of “Moderate Buy” from the thirteen analysts that are covering the company, Marketbeat reports. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $271.29.

A number of equities research analysts have recently weighed in on the company. Morgan Stanley assumed coverage on Inspire Medical Systems in a research report on Tuesday, March 19th. They set an “overweight” rating and a $250.00 target price for the company. KeyCorp began coverage on Inspire Medical Systems in a research report on Tuesday, February 6th. They set an “overweight” rating and a $278.00 target price for the company. Jefferies Financial Group began coverage on Inspire Medical Systems in a research note on Friday, January 19th. They set a “buy” rating and a $245.00 price objective for the company. Stifel Nicolaus reaffirmed a “hold” rating and set a $210.00 price objective on shares of Inspire Medical Systems in a research note on Tuesday, January 2nd. Finally, Mizuho reaffirmed a “buy” rating and set a $250.00 price objective on shares of Inspire Medical Systems in a research note on Wednesday, March 27th.

Insider Buying and Selling at Inspire Medical Systems

In other Inspire Medical Systems news, CEO Timothy P. Herbert sold 40,000 shares of the business’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $205.09, for a total value of $8,203,600.00. Following the completion of the transaction, the chief executive officer now directly owns 63,658 shares of the company’s stock, valued at $13,055,619.22. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, Director Jerry C. Griffin sold 554 shares of the business’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $197.81, for a total value of $109,586.74. Following the sale, the director now directly owns 10,636 shares in the company, valued at $2,103,907.16. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Timothy P. Herbert sold 40,000 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $205.09, for a total value of $8,203,600.00. Following the completion of the sale, the chief executive officer now owns 63,658 shares in the company, valued at $13,055,619.22. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 61,371 shares of company stock valued at $12,213,828. Company insiders own 4.10% of the company’s stock.

Institutional Trading of Inspire Medical Systems

Institutional investors and hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP raised its holdings in Inspire Medical Systems by 72.8% during the third quarter. Wellington Management Group LLP now owns 976,972 shares of the company’s stock worth $193,870,000 after acquiring an additional 411,480 shares in the last quarter. OPTIMAS CAPITAL Ltd bought a new stake in Inspire Medical Systems during the fourth quarter worth about $3,861,000. Seven Eight Capital LP bought a new stake in Inspire Medical Systems during the third quarter worth about $1,558,000. Charles Schwab Investment Management Inc. raised its holdings in Inspire Medical Systems by 3.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 256,222 shares of the company’s stock worth $50,845,000 after acquiring an additional 7,838 shares in the last quarter. Finally, Canada Pension Plan Investment Board raised its holdings in Inspire Medical Systems by 29.7% during the third quarter. Canada Pension Plan Investment Board now owns 40,200 shares of the company’s stock worth $7,977,000 after acquiring an additional 9,200 shares in the last quarter. Institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Stock Down 0.7 %

INSP stock opened at $221.63 on Friday. The company has a market cap of $6.72 billion, a P/E ratio of -299.50 and a beta of 1.37. Inspire Medical Systems has a twelve month low of $123.27 and a twelve month high of $330.00. The business has a fifty day moving average of $201.23 and a 200-day moving average of $182.94.

Inspire Medical Systems (NYSE:INSP) last released its earnings results on Tuesday, February 6th. The company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.53. The company had revenue of $192.51 million during the quarter, compared to the consensus estimate of $186.75 million. Inspire Medical Systems had a negative return on equity of 3.93% and a negative net margin of 3.39%. The firm’s quarterly revenue was up 39.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.10 earnings per share. As a group, equities research analysts anticipate that Inspire Medical Systems will post -0.35 earnings per share for the current fiscal year.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.